Education
About Us
Working with TipRanks
Follow Us
Turnstone Biologics Corp. (TSBX)
NASDAQ:TSBX
TSBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.29 - $2.60
Previous CloseN/A
Volume78.23K
Average Volume (3M)338.96K
Market Cap
$8.23M
Enterprise Value-$12.85M
Total Cash (Recent Filing)$21.85M
Total Debt (Recent Filing)$690.00K
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Aug 13, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding23,140,348
10 Day Avg. Volume92,948
30 Day Avg. Volume338,964
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap-1.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit25.71
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$1.00Price Target Upside177.78% Upside
Rating ConsensusHold
Number of Analyst Covering0
Turnstone Biologics Corp. News
PremiumCompany Announcements
Turnstone Biologics Corp. Enters Merger Agreement with XOMA
PremiumCompany Announcements
Turnstone Biologics Reports Q1 Loss Amid Strategic Shift
PremiumCompany Announcements
Turnstone Biologics Reports 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company holds $28.9 M in cash, equivalents, and short-term investments and expects this to fund operations through mid-2026.
Future PotentialThe company’s pre-clinical, next-generation TIL program, TIDAL-02, could deliver value to whomever picks up Turnstone’s mantle.
Bears Say
Cash ConstraintsBased on estimated 1Q25 cash balance of ~$11M, the price target is being lowered to $0.40 from $3.75.
Price Target ReductionWith the removal of TIDAL-01 from estimates, the price target has been reduced to $1 from $3 and the MP rating is reiterated.
Program DiscontinuationTurnstone Biologics announced the discontinuation of their lead (and sole) clinical program, TIDAL-01.
Options Prices
Currently, No data available
---
Ownership Overview
4.30%
Insiders
2.81% Mutual Funds
0.46% Other Institutional Investors
92.07% Public Companies and
Individual Investors
TSBX FAQ
What was Turnstone Biologics Corp.’s price range in the past 12 months?
Turnstone Biologics Corp. lowest stock price was $0.29 and its highest was $2.60 in the past 12 months.
What is Turnstone Biologics Corp.’s market cap?
Turnstone Biologics Corp.’s market cap is $8.23M.
When is Turnstone Biologics Corp.’s upcoming earnings report date?
Turnstone Biologics Corp.’s upcoming earnings report date is Aug 13, 2025 which is in 19 days.
How were Turnstone Biologics Corp.’s earnings last quarter?
Turnstone Biologics Corp. released its earnings results on May 08, 2025. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.25.
Is Turnstone Biologics Corp. overvalued?
According to Wall Street analysts Turnstone Biologics Corp.’s price is currently Undervalued.
Does Turnstone Biologics Corp. pay dividends?
Turnstone Biologics Corp. does not currently pay dividends.
What is Turnstone Biologics Corp.’s EPS estimate?
Turnstone Biologics Corp.’s EPS estimate is -0.16.
How many shares outstanding does Turnstone Biologics Corp. have?
Turnstone Biologics Corp. has 23,140,348 shares outstanding.
What happened to Turnstone Biologics Corp.’s price movement after its last earnings report?
Turnstone Biologics Corp. reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Turnstone Biologics Corp.?
Currently, no hedge funds are holding shares in TSBX
Company Description
Turnstone Biologics Corp.
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Technical Analysis
Carisma Therapeutics
―
Cyclerion Therapeutics
―
Aprea Therapeutics
―
Dogwood Therapeutics
―
HCW Biologics
―